Allotment of 106668 Equity Shares to Promoter upon conversion of warrants into Equity Shares.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Fredun Pharmaceuticals has allotted 1,06,668 equity shares to its promoter, Mr. Fredun Nariman Medhora, by converting an equivalent number of convertible warrants. These warrants were originally issued on a preferential basis on December 29, 2025, following shareholder approval at an EGM on October 22, 2025, out of a total of 1,60,000 warrants held by the promoter. The promoter has now paid the balance 75% of the consideration (₹937.50 per warrant) to trigger the conversion, bringing the total amount paid to ₹1,250 per share. The equity shares carry a face value of ₹10 each with a premium of ₹1,240, taking the total consideration to about ₹10 crore. The newly issued shares rank pari passu with existing equity shares and were allotted in dematerialized form. About 53,332 warrants remain outstanding and may be converted in the future.
Existing shareholders face a minor equity dilution, while the promoter strengthens his stake and shows confidence by infusing additional capital into the company. The stock may see limited short-term impact, but the increased promoter holding is generally viewed positively by retail investors.